PDCD1 and head and neck squamous cell carcinoma: In particular, the discovery of CTLA-4 and PD-1/PD-L1, as well as the molecular targeted therapies pembrolizumab and navulizumab, have improved the overall survival of patients with metastatic or recurrent HNSCC (4, 5).